News
Covid-19 Serosurveillance: Antibody Detection After Infection And Vaccination
Serosurveillance (antibody testing) can be useful in determining the magnitude of pathogen exposure in a given population. Over a year’s worth of COVID-19 infections and expanding vaccination efforts have put the spotlight on serological testing.
Fluvoxamine: A Potential Treatment Candidate For Covid-19
Fluvoxamine, an antidepressant also known as ‘Luvox’, shows promise as a COVID-19 therapeutic by preventing severe illness. The drug may have the ability to reduce inflammation and blood-clotting associated with COVID-19. Enable Biosciences CEO Dr. David Seftel observes the effects of fluvoxamine in Golden Gate Fields racetrack employees who were recently diagnosed with COVID-19.
Scientist Spotlight: Malvika Singhal
Welcome to Enable Biosciences’ Scientist Spotlight, a semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.
JDRF Launches First Mass Screening Program For Early-Stage Type 1 Diabetes (T1D) Detection
New York, NY and Red Bank, NJ, December 8, 2020 – On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research, has launched a groundbreaking screening initiative for T1D: T1Detect. Designed to make early detection of T1D easier and more accessible to a broad population, financial assistance is available for the cost of the screening. The initiative is supported by founding sponsor Provention Bio (Nasdaq: PRVB), a biopharmaceutical company focused on intercepting and preventing autoimmune disease.
An Easier Way to Detect Neutralizing Antibodies
Scientists at Enable Biosciences issued a pre-print describing a novel cell-free in-vitro assay that can determine the neutralization or killing capacity of antibodies against SARS-CoV-2, the virus responsible for COVID-19.
An Update On Our Validation Study
Several weeks ago, I posted a Call to Action asking for volunteers to contribute to a validation study for our antibody assay. The response was overwhelmingly positive. We have now enrolled over 150 people from across the country into our study. With all your help, we are so close to finalizing our validation study - we just need a few more local participants, we will mail you a kit! Sign up here: SARS CoV 2 Donors
Help Us Validate Our Coronavirus Test
After several weeks of work, our prototype assay shows >99% accuracy — but we need your help to get more samples for our IRB-approved validation study.